IMMY19114 /CC-220-MM-001/ Brea LipeResearch Question:
What is the maximum tolerated dose, safety, and efficacy of CC-220 as a single therapy
and in combination with other treatments in subjects with Multiple Myeloma?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study
consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in
combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination
with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of
the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple
Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.
Study Reference #: IMMY19114
Lead Researcher (Principal Investigator)
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search